Study reveals blood proteins predict risk of developing many diverse diseases
Researchers predicted the onset of 67 diseases, out-performing current standard models
Read More
Tag: GSK
GSK shares promising results from shingles vaccine trial
The varicella zoster virus that causes shingles and chicken pox is typically present in over 90% of adults globally
Read More
Patients in UK get early access to GSK’s Jemperli
It concerns the treatment being combined with platinum-containing chemotherapy
Read More
GSK’s Arexvy authorised by MHRA
Therapy is the first respiratory syncytial virus vaccine specifically developed for older adults
Read More
CHMP gives positive opinion recommending authorisation to GSK’s CKD drug
Chronic kidney disease affects roughly 700 million patients worldwide
Read More
GSK’s anaemia drug gets FDA advisory committee support for patients on dialysis
A final decision for daprodustat by the FDA is expected by 1 February 2023
Read More
New drug application accepted by FDA for GSK’s momelotinib
Therapy for the treatment of myelofibrosis has received significant results from phase 3 trial
Read More
Sanofi and GSK report successful efficacy results against Omicron
COVID-19 Beta-containing vaccine provides 75.1% efficacy in participants previously infected with coronavirus
Read More
Data delivery: Sanofi and GSK seek authorisation for COVID-19 vaccine
Pharma giants take major stride as vaccine shows significant increase in neutralising antibodies
Read More
Haleon days: GSK explains demerger decision
New company Haleon will become standalone venture as GSK’s strategy for the future unfolds
Read More
GSK plans UK headquarters for new consumer healthcare company
The new consumer healthcare company will be based at a newly built campus in Weybridge
Read More
‘New’ GSK spotlights growth potential of vaccines and speciality medicines
British drugmaker predicted a substantial £33bn sales ambition by 2031 in investor update
Read More
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
- Johnson & Johnson seeks EMA approval for teclistamab–daratumumab combination
- HUTCHMED begins phase 3 stage of pancreatic cancer trial
- Zenas reports strong phase 3 results for obexelimab in IgG4-related disease
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
